To push the envelope – increasing survival and decreasing toxicity – companies are harnessing new technology and mechanisms of action to develop the next generation of oncology drugs. Read More
With oncolytic virus therapeutics continuing to demonstrate their clinical potential in immuno-oncology, they have become hot commodities with companies looking to gain a foothold in the space. As a result, biotechnology companies with promising technologies are attracting the attention of major biopharmaceutical companies. In part 2 of our feature on oncolytic viruses, we examine the deals landscape in this area, which in the past 12 months has generated a number of major transactions involving big pharma companies. Read More
